S241656 clinical trials

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.